Experimental Ebola Vaccinations to Resume in Democratic Republic of Congo

In response to a new outbreak, health workers will start administering vaccines again soon.

Aug 6, 2018
Ashley Yeager

Health workers in eastern Democratic Republic of Congo (DRC) will begin administering vaccinations against a new outbreak of Ebola virus starting Wednesday (August 8), Reuters reports. 

The vaccine is experimental, but was used on a wide scale to combat the outbreak in northwestern Congo that was declared over two weeks again (July 24). Still, thousands of doses remain in the country’s capital, Kinshasa. Using the remaining vaccine doses in the new outbreak is “common sense,” a DRC Ministry of Public Health spokesperson tells ScienceInsider, because both scientific and ethical committees have already given the go ahead to continue to study the effectiveness of the vaccine. In the earlier outbreak, preliminary data indicate that 3,300 individuals were vaccinated and none of them became infected with Ebola, ScienceInsider reports. 

The current outbreak is in the North Kivu region, on the opposite side of DRC from the last outbreak. Barthe Ndjoloko, who oversees the health ministry’s Ebola response, tells Reuters that health workers and individuals who have come in contact with people infected with Ebola will be vaccinated. “Teams are conducting investigations on the ground to identify the contacts of the confirmed cases, including health workers,” he says.

Still, hurdles remain in administering the remaining vaccine doses. Scientists have to confirm that the Zaire species of Ebola is the cause of the outbreak. Four Ebola virus species are known to cause disease in humans, and another species was recently identified in bats. Confirmation that the current outbreak is caused by the Zaire species, and thus could be effectively combatted with the experimental vaccine, could come as early as Tuesday (August 7), according to Peter Salama, head of the World Health Organization’s (WHO) Health Emergencies Programme in Geneva, Switzerland, ScienceInsider reports.

Another complication is that “this new cluster is occurring in an environment which is very different from where we were operating in the northwest,” Salama says in a WHO statement issued August 1. “This is an active conflict zone. The major barrier will be safely accessing the affected population.”

On August 3, the WHO announced there have been a total of 43 Ebola cases in the latest outbreak, including 33 deaths. More than one million displaced people are currently residing in the affected region, which shares borders with Rwanda and Uganda. Individuals frequently cross the border for trade, which, combined with humanitarian and security issues in the region, could make the outbreak harder to contain.

“On the scale of degree of difficulty, trying to extinguish an outbreak of a deadly, high-threat pathogen in a war zone reaches the top of any of our scales,” Salama tells ScienceInsider.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!